Biophysical aspects of photodynamic therapy

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 25, Issue 1-2, 2006, Pages 7-28

  Juzeniene, Asta ^a   Nielsen, Kristian Pagh ^b   Moan, Johan ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Photodegradation (photobleaching); Photodynamic therapy; Photosensitizers; Singlet oxygen

Indexed keywords

AMINOLEVULINIC ACID; CHLORINE; CHOLESTEROL; DEUTERIUM OXIDE; HEMATOPORPHYRIN; HEMOGLOBIN; OXYHEMOGLOBIN; PHOTOFRIN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE ALUMINUM; PROTOPORPHYRIN; SINGLET OXYGEN; TETRAPHENYLPORPHYRIN DERIVATIVE; UROPORPHYRIN;

APOPTOSIS; BASAL CELL CARCINOMA; BIOPHYSICS; CARCINOGENIC ACTIVITY; CARCINOGENICITY; CELL ACTIVITY; CELL DEATH; CELL KILLING; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; DIFFUSION; DNA DAMAGE; DRUG BINDING; ENERGY TRANSFER; FLUORESCENCE; HUMAN; HYBRID CELL; IONIZING RADIATION; LIGHT EMITTING DIODE; LIGHT EXPOSURE; LYSOSOME; METASTASIS; MICROTUBULE; MUTATION; NONHUMAN; OXIDATION KINETICS; OXYGEN CONSUMPTION; PH MEASUREMENT; PHOSPHORESCENCE; PHOTOCHEMISTRY; PHOTODEGRADATION; PHOTODYNAMIC THERAPY; PHOTOOXIDATION; PRIORITY JOURNAL; QUANTUM YIELD; REVIEW; SKIN SENSITIVITY; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR CELL DESTRUCTION; TUMOR LOCALIZATION;

EID: 33644768304     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.v25.i1-2.20     Document Type: Review

References (166)

1. Green C, Diffey BL, Hawk JL. Ultraviolet radiation in the treatment of skin disease. Phys Med Biol 1992; 37(1):1-20.
2. Weishaupt KR, Gomer CJ, Dougherty TJ. Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. Cancer Res 1976; 36(7 Pt 1):2326-2329.
3. Fuchs J, Thiele J. The role of oxygen in cutaneous photodynamic therapy. Free Radic Biol Med 1998; 24(5):835-847.
4. Valenzeno DP. Photomodification of biological membranes with emphasis on singlet oxygen mechanisms. Photochem Photobiol 1987; 46(1):147-160.
5. 2 hypothesis as a driving force in recent research. Photochem Photobiol 1978; 28(4-5):493-508.
6. Sharman WM, Allen CM, van Lier JE. Photodynamic therapeutics: basic principles and clinical applications. Drug Discov Today 1999; 4(11):507-517.
7. Spikes JD. The historical development of ideas on applications of photosensitized reactions in health sciences. In: Bergasson R, Jori G, Land EJ, Truscott TG, editors. Primary Photoprocesses in Biology and Medicine. New York: Plenum Press, 1985; 209-227.
8. Finsen NR. Phototherapy. London: Edward Arnold, 1901; translated by JH Sequira.
9. Cauvin JF. Des bienfaits de l'insolation. In: Paris: Thesis, University of Paris, France, 1815.
10. Prime J. Les Accidentes Toxiques par L'Eosinate de Sodium. Paris: Jouve and Boyer; 1900.
11. Raab O. Uber die Wirkung fluoreszierender Stoffe auf Infusorien. Z Biol 1900; 39:524-546.
12. Von Tappeiner H. Uber die Wirkung fluoreszierenden Stoffe auf Infusorien nach Versuchen von O. Raab Muench Med Wochenschr 1900; 47:5-15.
13. Von Tappeiner H, Jesionek A. Therapeutische Versuche mit fluoreszierenden Stoffen. Muench Med Wochenschr 1903; 47:2042-2044.
14. Von Tappeiner H, Jodlbauer A. Uber die wirkung der photodynamischen (fluorescierenden) stoffe auf protozoan und enzyme. Dtsch Arch Klin Med 1904; 80:427-487.
15. Hausmann W. Die senibilisierende wirkung des hematoporphyrins. Biochem Z 1911; 30:276-316.
16. Meyer-Betz F. Untersuchungen uber die biologische (photodynamische) wirkung des hamatopotphyrins und anderer derivative des blut- und galenfarbstoffs. Dtsch Arch Klin Med 1913; 112:476-503.
17. Policard A. Etudes sur les aspects offerts par des tumeurs experimentales examinees a la lumiere de Wood. C R Soc Biol 1924; 91:1423-1428.
18. Körbler J. Untersuchung von krebsgewebe im fluoreszenerregenden licht. Strahlentherapie 1931; 41:510-518.
19. Auler H, Banzer G. Untersuchungen uber die rolle der porphyrine bei geschwulstkranken menschen und tieren. Z Krebsforsch 1942; 53:65-68.
20. Figge FHJ, Strong LC, Strong LC Jr, Shanbrom A. Fluorescent porphyrins in Harderian glands and susceptibility to spontaneous mammary carcinoma in mice. Cancer Res 1942; 2:335-342.
21. Kosaki T, Hasegawa S, Nakagawa S, Fujimura NUM, Saka T, Kotani Y, Muraki K. Studies on malignolipin IV. Detection of malignolipin in blood of normal persons and patients with various kinds diseases including malignant tumors. Mie Medical J 1960; X(3):387-410.
22. Kosaki T, Ikeda T, Takatsuka Y, Saka T. Studies on the affinities of cells and their formative elements for porphyrin bodies. Mie Medical J 1955; V(1-2):7-15.
23. Moan J, Christensen T. Porphyrins as tumor localizing agents and their possible use in photochemotherapy of cancer. Tumor Res 1980; 15:1-10.
24. Moan J, Peng Q. An outline of the hundred-year history of PDT. Anticancer Res 2003; 23(5A):3591-3600.
25. Dougherty TJ, Henderson BW, Schwartz S, Winkelman JW, Lipson RL. Historical Perspective. In: Dougherty TJ, Henderson BW, editors. Photodynamic therapy. New York: Marcel Dekker; 1992. p. 1-15.
26. Kick G, Messer G, Plewig G. Historical development of photodynamic therapy. Hautarzt 1996; 47(8):644-649.
27. Daniell MD, Hill JS. A history of photodynamic therapy. Aust N Z J Surg 1991; 61(5):340-348.
28. Dougherty TJ. A brief history of clinical photodynamic therapy development at Roswell Park Cancer Institute. J Clin Laser Med Surg 1996; 14(5)219-221.
29. Ackroyd R, Kelty C, Brown N, Reed M. The history of photodetection and photodynamic therapy. Photochem Photobiol 2001; 74(5):656-669
30. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer 2003; 3(5):380-387.
31. Moan J, Wold E. Detection of singlet oxygen production by ESR. Nature 1979; 279(5712):450-451.
32. Sharman WM, Allen CM, van Lier JE. Role of activated oxygen species in photodynamic therapy. Methods Enzymol 2000; 319:376-400.
33. Gorman AA, Rodgers MA. Current perspectives of singlet oxygen detection in biological environments. J Photochem Photobiol B 1992; 14(3):159-176.
34. Girotti AW. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res 1998; 39(8):1529-1542.
35. Girotti AW, Korytowski W. Cholesterol as a singlet oxygen detector in biological systems. Methods Enzymol 2000; 319:85-100.
36. Min DB, Boff JM. Chemistry and reaction of singlet oxygen in foods. Comprehensive Rev Food Sci Food Safety 2002; 1:58-72.
37. Moan J, Sommer S. Oxygen dependence of the photosensitizing effect of hematoporphyrin derivative in NHIK 3025 cells. Cancer Res 1985; 45(4):1608-1610.
38. Henderson BW, Fingar VH. Relationship of tumor hypoxia and response to photodynamic treatment in an experimental mouse tumor. Cancer Res 1987; 47(12):3110-3114.
39. Brown JM. The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1999; 59(23):5863-5870.
40. Newell B, Bedlow AJ, Cliff S, Drysdale SB, Stanton AW, Mortimer PS. Comparison of the microvasculature of basal cell carcinoma and actinic keratosis using intravital microscopy and immunohistochemistry. Br J Dermatol 2003; 149(1):105-110.
41. Stanton AW, Drysdale SB, Patel R, Mellor RH, Duff MJ, Levick JR, Mortimer PS. Expansion of microvascular bed and increased solute flux in human basal cell carcinoma in vivo, measured by fluorescein video angiography. Cancer Res 2003; 63(14):3969-3979.
42. Moan J, Berg K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol 1991; 53(4):549-553.
43. Moan J, Berg K, Bommer JC, Western A. Action spectra of phthalocyanines with respect to photosensitization of cells. Photochem Photobiol 1992; 56(2):171-175.
44. Moan J, Christensen T. Photodynamic effects on human cells exposed to light in the presence of hematoporphyrin. Localization of the active dye. Cancer Lett 1981; 11(3):209-214.
45. Moan J, Sommer S. Action spectra for hematoporphyrin derivative and Photofrin II with respect to sensitization of human cells in vitro to photoinactivation. Photochem Photobiol 1984; 40(5):631-634.
46. Noodt BB, Moan J, Kvam E, Steen HB. No correlation between DNA strand breaks and HPRT mutation induced by photochemical treatment in V79 cells. Mutat Res 1994; 323(1-2):75-79.
47. Ruck A, Kollner T, Dietrich A, Strauss W, Schneckenburger H. Fluorescence formation during photodynamic therapy in the nucleus of cells incubated with cationic and anionic water-soluble photosensitizers. J Photochem Photobiol B 1992; 12(4):403-412.
48. Kvam E, Stokke T, Moan J, Steen HB. Plateau distributions of DNA fragment lengths produced by extended light exposure of extranuclear photosensitizers in human cells. Nucleic Acids Res 1992; 20(24):6687-6693.
49. Moan J, Kvam E, Hovig E, Berg K. Effects of PDT on DNA and chromosomes. In: Riklis E, editor. Photobiology. New York: Plenum Press; 1991. p. 821-829.
50. Kvam E, Stokke T, Moan J. The lengths of DNA fragments light-induced in the presence of a photosensitizer localized at the nuclear membrane of human cells. Biochim Biophys Acta 1990; 1049(1):33-37.
51. Sharfaei S, Juzenas P, Moan J, Bissonnette R. Weekly topical application of methyl aminolevulinate followed by light exposure delays the appearance of UV-induced skin tumours in mice. Arch Dermatol Res 2002; 294(5):237-242.
52. Moan J, Peng Q, Evensen JF, Berg K, Western A, Rimington C. Photosensitizing efficiencies, tumor- and cellular uptake of different photosensitizing drugs relevant for photodynamic therapy of cancer. Photochem Photobiol 1987; 46(5):713-721.
53. Nelson JS, Sun CH, Berns MW. Study of the in vivo and in vitro photosensitizing capabilities of uroporphyrin I compared to photofrin II. Lasers Surg Med 1986; 6(2):131-136.
54. Moan J. Effect of bleaching of porphyrin sensitizers during photodynamic therapy. Cancer Lett 1986; 33(1):45-53.
55. Moan J. A change in the quantum yield of photoinactivation of cells observed during photodynamic treatment. Lasers Med Sci 1988; 3:93-97.
56. Almeida RD, Manadas BJ, Carvalho AP, Duarte CB. Intracellular signaling mechanisms in photodynamic therapy. Biochim Biophys Acta 2004; 1704(2):59-86.
57. Agostinis P, Buytaert E, Breyssens H, Hendrickx N. Regulatory pathways in photodynamic therapy induced apoptosis. Photochem Photobiol Sci 2004; 3(8):721-729.
58. Luksiene Z. Photodynamic therapy: mechanism of action and ways to improve the efficiency of treatment. Medicina (Kaunas) 2003; 39(12):1137-1150.
59. Murphy FJ, Seery LT, Hayes I. Therapeutic approaches to the modulation of apoptosis. Essays Biochem 2003; 39:131-153.
60. Piette J, Volanti C, Vantieghem A, Matroule JY, Habraken Y, Agostinis P. Cell death and growth arrest in response to photodynamic therapy with membrane-bound photosensitizers. Biochem Pharmacol 2003; 66(8):1651-1659.
61. Oleinick NL, Morris RL, Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci 2002; 1(1):1-21.
62. Davies CL, Ranheim T, Malik Z, Rofstad EK, Moan J, Lindmo T. Relationship between changes in antigen expression and protein synthesis in human melanoma cells after hyperthermia and photodynamic treatment. Br J Cancer 1988; 58(3):306-313.
63. Moan J, Johannessen JV, Christensen T, Espevik T, McGhie JB. Porphyrin-sensitized photoinactivation of human cells in vitro. Am J Pathol 1982; 109(2):184-192.
64. Moan J, Vistnes AI. Porphyrin photosensitization of proteins in cell membranes as studied by spin-labelling and by quantification of DTNB-reactive SH-groups. Photochem Photobiol 1986; 44(1):15-19.
65. van Steveninck J, Dubbelman TM, Verweij H. Photodynamic membrane damage. Adv Exp Med Biol 1983; 160:227-240.
66. Christensen T, Moan J, Wibe E, Oftebro R. Photodynamic effect of haematoporphyrin throughout the cell cycle of the human cell line NHIK 3025 cultivated in vitro. Br J Cancer 1979; 39(1):64-68.
67. Berg K, Moan J. Photodynamic effects of Photofrin II on cell division in human NHIK 3025 cells. Int J Radiat Biol Relat Stud Phys Chem Med 1988; 53(5):797-811.
68. Kessel D, Luo Y. Photodynamic therapy: a mitochondrial inducer of apoptosis. Cell Death Differ 1999; 6(1):28-35.
69. Kessel D, Luo Y. Mitochondrial photodamage and PDT-induced apoptosis. J Photochem Photobiol B 1998; 42(2):89-95.
70. Kessel D, Luo Y, Deng Y, Chang CK. The role of subcellular localization in initiation of apoptosis by photodynamic therapy. Photochem Photobiol 1997; 65(3):422-426.
71. Wyld L, Reed MW, Brown NJ. Differential cell death response to photodynamic therapy is dependent on dose and cell type. Br J Cancer 2001; 84(10):1384-1386.
72. Slater TF, Riley PA. Photosensitization and lysosomal damage. Nature 1966; 209(19):151-154.
73. Moan J, Berg K, Kvam E, Western A, Malik Z, Ruck A, Schneckenburger H. Intracellular localization of photosensitizers. Ciba Found Symp 1989; 146:95-107.
74. Moan J, Berg K, Steen HB, Warloe T, Madslien K. Fluorescence and photodynamic effects of phthalocyanines and porphyrins in cells. In: Henderson B, Dougherty T, editors. Photodynamic Therapy: Basic Principles and Clinical Applications. New York: Marcel Dekker; 1992. p. 19-36.
75. Moan J, Berg K, Peng Q, Ma LW. On the action. Mechanisms of photochemotherapy of cancer. In: Jung EG, Holick M, de Gruyter W, editors. Biological Effects of Light. New York: Berling; 1993. p. 337-349.
76. Berg K, Selbo PK, Prasmickaite L, Tjelle TE, Sandvig K, Moan J, Gaudernack G, Fodstad O, Kjolsrud S, Anholt H, Rodal GH, Rodal SK, Hogset A. Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. Cancer Res 1999; 59(6):1180-1183.
77. Moan J, Berg K, Anholt H, Madslien K. Sulfonated aluminium phthalocyanines as sensitizers for photochemotherapy. Effects of small light doses on localization, dye fluorescence and photosensitivity in V79 cells. Int J Cancer 1994; 58(6):865-870.
78. Moan J, Anholt H, Peng Q. A transient reduction of the fluorescence of aluminium phthalocyanine tetrasulphonate in tumours during photodynamic therapy. J Photochem Photobiol B 1990; 5(1):115-119.
79. Anholt H, Moan J. Fractionated treatment of CaD2 tumors in mice sensitized with aluminium phthlocyanine tetrasulfonate. Cancer Lett 1992; 61(3):263-267.
80. Moan J, Peng Q, Iani V, Ma LW, Horobin RW, Berg K, Kongshaug M, Nesland JM. Biodistribution, pharmacokinetic and in vivo fluorescence spectroscopic studies of photosensitizers. In: Ehrenberg B, Jori G, Moan J, editors. Photochemotherapy: Photodynamic Therapy and Other Modalities. Proc. SPIE 2625:1996:234-250.
81. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q. Photodynamic therapy. J Natl Cancer Inst 1998; 90(12):889-905.
82. Moan J, Peng Q, Sorensen R, Iani V, Nesland JM. The biophysical foundations of photodynamic therapy. Endoscopy 1998; 30(4):387-391.
83. Moan J, van den Akker JT, Juzenas P, Ma LW, Angel-Petersen E, Gadmar QB, Iani V. On the basis for tumor selectivity in the 5-aminolevulinic acid-induced synthesis of protoporphyrin IX. J Porphyrins Phthalocyanines 2001; 5:170-176.
84. Korbelik M, Krosl G, Olive PL, Chaplin DJ. Distribution of Photofrin between tumour cells and tumour associated macrophages. Br J Cancer 1991; 64(3):508-512.
85. Dvorak HF. Leaky tumor vessels: consequences for tumor stroma generation and for solid tumor therapy. Prog Clin Biol Res 1990; 354A:317-330.
86. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987; 47(12):3039-3051.
87. Volk T, Jahde E, Fortmeyer HP, Glusenkamp KH, Rajewsky MF. pH in human tumour xenografts: effect of intravenous administration of glucose. Br J Cancer 1993; 68(3):492-500.
88. Griffiths JR. Are cancer cells acidic? Br J Cancer 1991; 64(3):425-427.
89. Gerweck LE, Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res 1996; 56(6):1194-1198.
90. Gerweck LE. The pH difference between tumor and normal tissue offers a tumor specific target for the treatment of cancer. Drug Resist Update 2000; 3(1):49-50.
91. Pottier R, Kennedy JC. The possible role of ionic species in selective biodistribution of photochemotherapeutic agents toward neoplastic tissue. J Photochem Photobiol B 1990; 8(1):1-16.
92. Wike-Hooley JL, Haveman J, Reinhold HS. The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol 1984; 2(4):343-366.
93. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989; 49(16):4373-4384.
94. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989; 49(23):-6449-6465.
95. Moan J, Cunderlikova B, Juzeniene A, Juzenas P, Ma LW, Iani V. Tumour selectivity of photodynamic therapy. In: Bruland QS, Flægstand T, editors. Targeted Cancer Therapies. Tromsø Symposium: University Library of Tromsø, 2003:208-211.
96. Moan J, Ma LW, Iani V. On the pharmacokinetics of topically applied 5-aminolevulinic acid and two of its esters. Int J Cancer 2001; 92(1):139-143.
97. Wennberg AM, Larko O, Lonnroth P, Larson G, Krogstad AL. Delta-aminolevulinic acid in superficial basal cell carcinomas and normal skin-a microdialysis and perfusion study. Clin Exp Dermatol 2000; 25(4):317-322.
98. Wennberg AM. Basal cell carcinoma - new aspects of diagnosis and treatment. Acta Derm Venereol Suppl (Stockh) 2000; 209:5-25.
99. Song CW. Effect of local hyperthermia on blood flow and microenvironment: a review. Cancer Res 1984; 44(10 Suppl):4721s-4730s.
100. Moan J, Berg K, Gadmar OB, Iani V, Ma L, Juzenas P. The temperature dependence of protoporphyrin IX production in cells and tissues. Photochem Photobiol 1999; 70(4):669-673.
101. Gibson SL, Cupriks DJ, Havens JJ, Nguyen ML, Hilf R. A regulatory role for porphobilinogen deaminase (PBGD) in delta-aminolaevulinic acid (delta-ALA)-induced photosensitization. Br J Cancer 1998; 77(2):235-243.
102. el Sharabasy MM, el Waseef AM, Hafez MM, Salim SA. Porphyrin metabolism in some malignant diseases. Br J Cancer 1992; 65(3):409-412.
103. Van Hillegersberg R, Van den Berg JW, Kort WJ, Terpstra OT, Wilson JH. Selective accumulation of endogenously produced porphyrins in a liver metastasis model in rats. Gastroenterology 1992; 103(2):647-651.
104. Rittenhouse-Diakun K, van Leengoed H, Morgan J, Hryhorenko E, Paszkiewicz G, Whitaker JE, Oseroff AR. The role of transferrin receptor (CD71) in photodynamic therapy of activated and malignant lymphocytes using the heme precursor delta-aminolevulinic acid (ALA). Photochem Photobiol 1995; 61(5):523-528.
105. Peng Q, Moan J, Farrants G, Danielsen HE, Rimington C. Localization of potent photosensitizers in human tumor LOX by means of laser scanning microscopy. Cancer Lett 1990; 53(2-3):129-139.
106. Kaestner L, Juzeniene A, Moan J. Erythrocytes-the 'house elves' of photodynamic therapy. Photochem Photobiol Sci 2004; 3(11-12):981-989.
107. Henderson BW, Vaughan L, Bellnier DA, van Leengoed H, Johnson PG, Oseroff AR. Photosensitization of murine tumor, vasculature and skin by 5-aminolevulinic acid-induced porphyrin. Photochem Photobiol 1995; 62(4):780-789.
108. Tsoukas MM, Gonzalez S, Flotte TJ, Anderson RR, Sherwood ME, Kollias N. Wavelength and fluence effect on vascular damage with photodynamic therapy on skin. J Invest Dermatol 2000; 114(2):303-308.
109. Korbelik M. Induction of tumor immunity by photodynamic therapy. J Clin Laser Med Surg 1996; 14(5):329-334.
110. Korbelik M, Dougherty GJ. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res 1999; 59(8):1941-1946.
111. van Duijnhoven FH, Aalbers RI, Rovers JP, Terpstra OT, Kuppen PJ. The immunological consequences of photodynamic treatment of cancer, a literature review. Immunobiology 2003; 207(2):105-113.
112. Canti G, Ricci L, Cantone V, Franco P, Marelli O, Andreoni A, Cubeddu R, Nicolin A. Hematoporphyrin derivative photoradiation therapy in murine solid tumors. Cancer Lett 1983; 21(2):233-237.
113. Davies CD, Western A, Lindmo T, Moan J. Changes in antigen expression on human FME melanoma cells after exposure to photoactivated hematoporphyrin derivative. Cancer Res 1986; 46(12 Pt 1):6068-6072.
114. Hasan T, Ortel B, Moor ACE. Photodynamic therapy of cancer pogue, B.W. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC Jr., Gansler TS, Holland JS, Frei E III, editors. Holland-frei Cancer Medicine. Hamilton, Ontario: B.C. Decker Inc. 2003; 605-622.
115. Henderson BW, Busch TM, Vaughan LA, Frawley NP, Babich D, Sosa TA, Zollo JD, Dee AS, Cooper MT, Bellnier DA, Greco WR, Oseroff AR. Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate. Cancer Res 2000; 60(3)525-529.
116. Pogue BW, O'Hara JA, Goodwin IA, Wilmot CJ, Fournier GP, Akay AR, Swartz H. Tumor PO(2) changes during photodynamic therapy depend upon photosensitizer type and time after injection. Comp Biochem Physiol A Mol Integr Physiol 2002; 132(1):177-184.
117. Juzenas P, Sorensen R, Iani V, Moan J. Uptake of topically applied 5-aminolevulinic acid and production of protoporphyrin IX in normal mouse skin: dependence on skin temperature. Photochem Photobiol 1999; 69(4):478-481.
118. Juzeniene A, Juzenas P, Kaalhus O, Iani V, Moan J. Temperature effect on accumulation of protoporphyrin IX after topical application of 5-aminolevulinic acid and its methylester and hexylester derivatives in normal mouse skin. Photochem Photobiol 2002; 76(4):452-456.
119. van den Akker JT, Boot K, Vernon DI, Brown SB, Groenendijk L, van Rhoon GC, Sterenborg HJ. Effect of elevating the skin temperature during topical ALA application on in vitro ALA penetration through mouse skin and in vivo PpIX production in human skin. Photochem Photobiol Sci 2004; 3(3):263-267.
120. Severinghaus JW. Oxyhemoglobin dissociation curve correction for temperature and pH variation in human blood. J Appl Physiol 1958; 12(3):485-486.
121. Astrup P, Engel K, Severinghaus JW, Munson E. The influence of temperature and pH on the dissociation curve of oxyhemoglobin of human blood. Scand J Clin Lab Invest 1965; 17(6):515-523.
122. Bryan-Brown CW, Valeri CR, Altschule MD. The colouring substance of blood. Crit Care Med 1979; 7(9):358-359.
123. Veenhuizen RB, Stewart FA. The importance of fluence rate in photodynamic therapy: is there a parallel with ionizing radiation dose-rate effects? Radiother Oncol 1995; 37(2):131-135.
124. Tromberg BJ, Orenstein A, Kimel S, Barker SJ, Hyatt J, Nelson JS, Berns MW. In vivo tumor oxygen tension measurements for the evaluation of the efficiency of photodynamic therapy. Photochem Photobiol 1990; 52(2):375-385.
125. Tromberg BJ, Kimel S, Orenstein A, Barker SJ, Hyatt J, Nelson JS, Roberts WG, Berns MW. Tumor oxygen tension during photodynamic therapy. J Photochem Photobiol B 1990; 5(1):121-126.
126. Foster TH, Murant RS, Bryant RG, Knox RS, Gibson SL, Hilf R. Oxygen consumption and diffusion effects in photodynamic therapy. Radiat Res 1991; 126(3):296-303.
127. Zilberstein J, Bromberg A, Frantz A, Rosenbach-Belkin V, Kritzmann A, Pfefermann R, Salomon Y, Scherz A. Light-dependent oxygen consumption in bacteriochlorophyll-serine-treated melanoma tumors: on-line determination using a tissue-inserted oxygen microsensor. Photochem Photobiol 1997; 65(6):1012-1019.
128. Sitnik TM, Hampton JA, Henderson BW. Reduction of tumour oxygenation during and after photodynamic therapy in vivo: effects of fluence rate. Br J Cancer 1998; 77(9):1386-1394.
129. Pogue BW, Braun RD, Lanzen JL, Erickson C, Dewhirst MW. Analysis of the heterogeneity of pO2 dynamics during photodynamic therapy with verteporfin. Photochem Photobiol 2001; 74(5):700-706.
130. Sitnik TM, Henderson BW. The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy. Photochem Photobiol 1998; 67(4):462-466.
131. van Geel IP, Oppelaar H, Marijnissen JP, Stewart FA. Influence of fractionation and fluence rate in photodynamic therapy with Photofrin or mTHPC. Radiat Res 1996; 145(5):602-609.
132. Gibson SL, Foster TH, Feins RH, Raubertas RF, Fallon MA, Hilf R. Effects of photodynamic therapy on xenografts of human mesothelioma and rat mammary carcinoma in nude mice. Br J Cancer 1994; 69(3):473-481.
133. Moan J, Streckyte G, Bagdonas S, Bech O, Berg K. Photobleaching of protoporphyrin IX in cells incubated with 5-aminolevulinic acid. Int J Cancer 1997; 70(1):90-97.
134. Bonnett R, Martinez G. Photobleaching of sensitizers used in photodynamic therapy. Tetrahedron 2001; 57:9513-9547.
135. Moan J, Kessel D. Photoproducts formed from photofrin II in cells. J Photochem Photobiol B 1988; 1(4):429-436.
136. Gulliya KS, Chanh T, Harriman A, Aronoff BL, Matthews JL. Preactivation: a new concept for generation of photoproducts for potential therapeutic applications. Semin Surg Oncol 1992; 8(4):250-253.
137. Konig K, Schneckenburger H, Ruck A, Steiner R. In vivo photoproduct formation during PDT with ALA-induced endogenous porphyrins. J Photochem Photobiol B 1993; 18(2-3):287-290.
138. Gudgin Dickson EF, Pottier RH. On the role of protoporphyrin IX photoproducts in photodynamic therapy. J Photochem Photobiol B 1995; 29(1):91-93.
139. Rotomskis R, Bagdonas S, Streckyte G. Spectroscopic studies of photobleaching and photoproduct formation of porphyrins used in tumour therapy. J Photochem Photobiol B 1996; 33(1):61-67.
140. Amit I, Malik Z, Kessel D. Photoproduct formation from a zinc benzochlorin iminium salt detected by fluorescence microscopy. Photochem Photobiol 1999; 69(6):700-702.
141. Kasselouri A, Bourdon O, Demore D, Blais JC, Prognon P, Bourg-Heckly G, Blais J. Fluorescence and mass spectrometry studies of meta-tetra (hydroxyphenyl)chlorin photoproducts. Photochem Photobiol 1999; 70(3):275-279.
142. Edwards AM, Barredo F, Silva E, De Ioannes AE, Becker MI. Apoptosis induction in non-irradiated human HL-60 and murine NSO/2 tumor cells by photoproducts of indole-3-acetic acid and riboflavin. Photochem Photobiol 1999; 70(4):645-649.
143. Goyan RL, Cramb DT. Near-infrared two-photon excitation of protoporphyrin IX: photodynamics and photoproduct generation. Photochem Photobiol 2000; 72(6):821-827.
144. Brancaleon L, Moseley H. Effects of photoproducts on the binding properties of protoporphyrin IX to proteins. Biophys Chem 2002; 96(1):77-87.
145. Kyagova AA, Kozir LA, Mansurova GV, Zorin VP, Bezdetnaya LN, Guillemin F, Potapenko AY. Modulation of delayed type hypersensitivity in mice treated with photoproducts of various photosensitizers used in photodynamic therapy. Russ J Immunol 2002; 7(4):327-334.
146. Wessels JM, Sroka R, Heil P, Seidlitz HK. Photodegradation of protoporphyrin-dimethylester in solution and in organized environments. Int J Radiat Biol 1993; 64(5):475-484.
147. Charlesworth P, Truscott TG. The use of 5-aminolevulinic acid (ALA) in photodynamic therapy (PDT). J Photochem Photobiol B 1993; 18(1):99-100.
148. Kubat P, Zelinger Z, Jirsa M. The effect of the irradiation wavelength on the processes sensitized by protoporphyrin IX dimethyl ester. Radiat Res 1997; 148(4):382-385.
149. Bagdonas S, Ma LW, Iani V, Rotomskis R, Juzenas P, Moan J. Phototransformations of 5-aminolevulinic acid-induced protoporphyrin IX in vitro: a spectroscopic study. Photochem Photobiol 2000; 72(2):186-192.
150. Ericson MB, Grapengiesser S, Gudmundson F, Wennberg AM, Larko O, Moan J, Rosen A. A spectroscopic study of the photobleaching of protoporphyrin IX in solution. Lasers Med Sci 2003; 18(1):56-62.
151. Ma L, Bagdonas S, Moan J. The photosensitizing effect of the photoproduct of protoporphyrin IX. J Photochem Photobiol B 2001; 60(2-3):108-113.
152. Juzenas P, Iani V, Bagdonas S, Rotomskis R, Moan J. Fluorescence spectroscopy of normal mouse skin exposed to 5-aminolaevulinic acid and red light. J Photochem Photobiol B 2001; 61(1-2):78-86.
153. Berg K, Madslien K, Bommer JC, Oftebro R, Winkelman JW, Moan J. Light induced relocalization of sulfonated meso-tetraphenylporphines in NHIK 3025 cells and effects of dose fractionation. Photochem Photobiol 1991; 53(2):203-210.
154. Berg K, Western A, Bommer JC, Moan J. Intracellular localization of sulfonated meso-tetraphenylporphines in a human carcinoma cell line. Photochem Photobiol 1990; 52(3):481-487.
155. Peng Q, Brown SB, Moan J, Nesland JM, Wainwright M, Griffiths J, Dixon B, Cruse-Sawyer J, Vernon D. Biodistribution of a methylene blue derivative in tumor and normal tissues of rats. J Photochem Photobiol B 1993; 20(1):63-71.
156. Moan J. The photochemical yield of singlet oxygen from porphyrins in different states of aggregation. Photochem Photobiol 1984; 39:445-449.
157. Mang TS, Dougherty TJ, Potter WR, Boyle DG, Somer S, Moan J. Photobleaching of porphyrins used in photodynamic therapy and implications for therapy. Photochem Photobiol 1987; 45(4):501-506.
158. Wagner JR, Ali H, Langlois R, Brasseur N, van Lier JE. Biological activities of phthalocyanines - VI. Photooxidation of L-trypto phan by selectively sulfonated gallium phthalocyanines: singlet oxygen yields and effect of aggregation. Photochem Photobiol 1987; 45(5):587-594.
159. Moan J, Juzenas P, Bagdonas S. Degradation and transformation of photosensitisers during light exposure. Recent Res Dev. Photochem Photobiol 2000; 4:121-132.
160. Wilson BC, Patterson MS. The physics of photodynamic therapy. Phys Med Biol 1986; 31(4):327-360.
161. Panjehpour M, Overholt BF, Haydek JM. Light sources and delivery devices for photodynamic therapy in the gastrointestinal tract. Gastrointest Endosc Clin N Am 2000; 10(3):513-532.
162. Brancaleon L, Moseley H. Laser and non-laser light sources for photodynamic therapy. Lasers Med Sci 2002; 17(3):173-186.
163. Mang TS. Lasers and light sources for PDT: past, present and future. Photodiagnosis Photodyn Therapy 2004; 1:43-48.
164. Juzeniene A, Juzenas P, Ma LW, Iani V, Moan J. Effectiveness of different light sources for 5-aminolevulinic acid photodynamic therapy. Lasers Med Sci 2004; 19(3):139-149.
165. S. Prahl. S.Prahl has tabulated the molar extinction coefficients for oxy-hemoglobin and deoxy-hemoglobin using data from WB Gratzer and N Kollias. In: http://omlc.ogi.edu/spectra/hemoglobin/summary.html. Portland (OR): The Oregon Medical Laser Center;:2004.
166. Benesch RE, Benesch R. The mechanism of interaction of red cell organic phosphates with hemoglobin. Adv Protein Chem 1974; 28:211-237.